A pharmacogenetic-driven approach for controlled ovarian hyperstimulation by FSH treatment.
OBJECTIVE
The aim of this study was to develop a pharmacogenetic- (PGx) driven approach for a controlled ovarian hyperstimulation (COH) treatment protocol used for in vitro fertilization procedures. The enrolled patients were genotyped for a single nucleotide polymorphism (SNP) N680S, within the FSHR.


METHODS
Seventy-eight women, who had previously received at least two COH cycles without positive fertilization with FSH and AMH values <10 mUI/mL and >0.3 ng/mL respectively were enrolled. They were genotyped for N680S and then categorized in high (HR), intermediate (IR), and poor responders (PR). Each subgroup received a tailored FSH treatment of 100, 225, and 400 UI/mL, respectively. The response was evaluated considering differences with previous COH cycle in terms of number of follicles (FR), oocytes (OR), and embryos produced (EMB).


RESULTS
With regards to the endpoint considered comparing the non-PGx with the PGx approach, for what regards the FR a statistically significant increase of their numbers was observed with the PGx-tailored approach (HR P<0.0001; IR P=0.00892; PR P=0.0032). Similar statistical significant results were also achieved for OR but only for HR (P<0.0001) and IR (P=0.00169). Last but not least for the EMB (HR P<0.001; IR P=0.00670 and PR P<0.0001) all the different genotype considered achieved a statistical significance.


CONCLUSIONS
This study, although with a limited number of enrolled patients, showed that a FSH treatment with a PGx-driven approach might have the potential to improve COH clinical outcome.
GeXNano srl, Gerenzano, Varese, Italy - colognato@gexnano.com.
R
R
Colognato
R
R
Aiello
F
F
Dulcetti
A M
AM
Ruggeri
S
S
De Toffol
L
L
Marcato
A M
AM
Irollo
C
C
Criscuolo
M F
MF
Gangale
F
F
Maggi
G
G
Simoni
D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage*; D005838:Genotype; D006801:Humans; D009865:Oocytes / Q000378:metabolism; D006080:Ovarian Follicle / Q000378:metabolism; D010062:Ovulation Induction / Q000379:methods*; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011962:Receptors, FSH / Q000235:genetics*; D016896:Treatment Outcome
D011962:Receptors, FSH; D005640:Follicle Stimulating Hormone